Galapagos : We should have a gift under the tree

Buy, FV EUR52
News published on November Tuesday 17, 2015
Share on

We were pleased to welcome Andre Hoekema, Sr. VP Corporate Development at Galapagos, at a time when all eyes are turned on filgotinib, the company’s late stage pipeline asset which is expected to be partnered by year-end. Andre seems confident in the company’s ability to close a deal in the upcoming weeks with metrics better or as good as the ones from the ABBV deal. We do not rule out that the company has term sheets in hand. The Cystic Fibrosis programme is on track with several compounds expected to reach the clinic within the next 6 to 12 months.

For more information, please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities